NCT03556891

Pivotal Study of eCoin for Overactive Bladder With Urgency Urinary Incontinence

Pivotal Study of Subcutaneous Tibial Nerve Stimulation With eCoin for Overactive Bladder (OAB) With Urgency Urinary Incontinence (UUI)

• Status: Completed
• Phase: N/A
• Study type: Interventional
• Enrollment: 133 (actual)
• Sponsor: Valencia Technologies Corporation · Industry
• Sex: All
• Age: 18 Years – 80 Years
• Healthy volunteers: Not accepted

Summary

This trial is a prospective, multicenter, single-arm study of the safety and effectiveness of eCoinTM tibial nerve stimulation in subjects having overactive bladder (OAB) with urgency urinary incontinence (UUI). The study will evaluate changes from baseline in OAB symptoms as measured by voiding diaries and patient reported-outcomes through 48 weeks of eCoinTM therapy or 52 weeks of implantation.

Detailed description

This study enrolled and implanted 133 subjects at 15 sites in the US under the original IDE. Subjects were given the option to extend out to 3 years post activation, with annual visits at 2 and 3 years post activation (96 and 144 weeks post-activation). Subjects who are still active in the original IDE study will be offered consecutive enrollment in the post approval study and will be given the option to receive a new implant. Subjects who are no longer active, or have exited the study will be given the option to reenter the study and complete two follow-up visits. Subjects re-entering the study will not have the option to receive a new implant. Post approval follow-up of subjects will occur through the year 5 visit (257 weeks post-activation of their original device). Reimplantation of a new eCoin would not reset their follow-up clock.

Conditions

• Overactive Bladder
• Urge Incontinence
• Incontinence, Urinary
• Urinary Urge Incontinence

Interventions

Type	Name	Description
DEVICE	eCoin Tibial Nerve Stimulation	Subcutaneous stimulation of the tibial nerve using the eCoin device.

Timeline

• Start date: 2018-09-04
• Primary completion: 2020-04-12
• Completion: 2024-09-18
• First posted: 2018-06-14
• Last updated: 2025-10-02
• Results posted: 2021-07-30

Locations

15 sites across 1 country: United States

Regulatory

• FDA-regulated device study